Mother-infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination

Vaccine

Volumn 29, Issue 28, 2011, Pages 4565-4575

  Holmlund, Emma ^a   Nohynek, Hanna ^a   Quiambao, Beatriz ^b   Ollgren, Jukka ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

Author keywords

23 Valent pneumococcal polysaccharide vaccine; Infant immunization; Maternal antibodies; Maternal immunization

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MATERNAL ANTIBODY; PNEUMO23; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; DRUG FEVER; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEROTYPE; SIDE EFFECT; SOMNOLENCE; UMBILICAL CORD BLOOD; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CHILD, PRESCHOOL; FEMALE; FETAL BLOOD; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; INFANT; PHILIPPINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 79958160311     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.068     Document Type: Article

References (52)

1. Scott J.A.G. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007, 25(13):2398-2405.
2. Lupisan S.P., Herva E., Sombrero L.T., Quiambao B.P., Capeding M.R., Abucejo P.E., et al. Invasive bacterial infections of children in a rural province in the central Philippines. Am J Trop Med Hyg 2000, 62(3):341-346.
3. Lucero M.G., Nohynek H., Williams G., Tallo V., Simoes E.A., Lupisan S., et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009, 28(6):455-462.
4. The WHO Young Infants Study Group Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis J 1999, 18(Suppl 10):S17-S22.
5. Clark A., Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009, 373(9674):1543-1549.
6. Lehmann D., Pomat W.S., Riley I.D., Alpers M.P. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine 2003, 21(24):3446-3450.
7. Munoz F.M., Englund J.A., Cheesman C.C., Maccato M.L., Pinell P.M., Nahm M.H., et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001, 20(5-6):826-837.
8. Deubzer H.E., Obaro S.K., Newman V.O., Adegbola R.A., Greenwood B.M., Henderson D.C. Colostrum obtained from women vaccinated with pneumococcal vaccine during pregnancy inhibits epithelial adhesion of Streptococcus pneumoniae. J Infect Dis 2004, 190(10):1758-1761.
9. Douglas R.M., Paton J.C., Duncan S.J., Hansman D.J. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983, 148(1):131-137.
10. Koskela M., Leinonen M., Häivä V., Timonen M., Mäkelä P. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis J 1986, 5(1):45-50.
11. Sell S., Wright P., Vaughn W., Thompson J., Schiffman G. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis 1981, 3(Suppl):S97-107.
12. Temple K., Greenwood B., Inskip H., Hall A., Koskela M., Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 1991, 10(5):386-390.
13. Riley I.D., Lehmann D., Alpers M.P., Marshall T.F., Gratten H., Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986, 2(8512):877-881.
14. Pavia M., Bianco A., Nobile C.G.A., Marinelli P., Angelillo I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123(6):e1103-e1110.
15. Prymula R., Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vac 2009, 8(11):1479-1500.
16. Reinert R.R., Paradiso P., Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vac 2010, 9(3):229-236.
17. Pomat W., Phuanukoonnon S., Van den Biggelaar A., Francis J., Orami T., Jacoby P., et al. Immunogenicity of neonatal and early infant pneumococcal conjugate vaccination and pneumococcal polysaccharide vaccine booster in Papua New Guinea. Proceedings of the international neonatal & maternal immunization symposium 2010.
18. Warira A., Goldblatt D., Ashton L., Ojal J., Muhoro A., Burbidge P., et al. Pneumococcal conjugate vaccine at birth is safe, immunogenic and protects against carriage. Proceedings of the 7th international symposium on pneumococci and pneumococcal infections 2010, [Abstr 28].
19. Quiambao B.P., Nohynek H.M., Käyhty H., Ollgren J.P., Gozum L.S., Gepanayao C.P., et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007, 25(22):4470-4477.
20. Quiambao B.P., Nohynek H., Kayhty H., Ollgren J., Gozum L., Gepanayao C.P., et al. Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 2003, 21(24):3451-3454.
21. Lehmann D., Pomat W.S., Combs B., Dyke T., Alpers M.P. Maternal immunization with pneumococcal polysaccharide vaccine in the highlands of Papua New Guinea. Vaccine 2002, 20(13-14):1837-1845.
22. O'Dempsey T.J., McArdle T., Ceesay S.J., Banya W.A., Demba E., Secka O., et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996, 14(10):963-970.
23. Shahid N.S., Steinhoff M.C., Hoque S.S., Begum T., Thompson C., Siber G.R. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet 1995, 346(8985):1252-1257.
24. CDC Recommended Adult Immunization Schedule-United States (ACIP). Morb Mortal Wkly Rep 2005, 54(40):Q1-Q4.
25. NHMRC. 2010 [14.04.11]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-pneumococcal.
26. CDC. Guidelines for vaccinating pregnant women (ACIP). 2007 [14.04.11]. http://www.cdc.gov/vaccines/pubs/downloads/b_preg_guide.pdf.
27. Russell F.M., Carapetis J.R., Balloch A., Licciardi P.V., Jenney A.W.J., Tikoduadua L., et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010, 28(19):3341-3349.
28. Käyhty H., Åhman H., Rönnberg P.R., Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995, 172(5):1273-1278.
29. Simell B., Lahdenkari M., Reunanen A., Kayhty H., Vakevainen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol 2008, 15(9):1391-1397.
30. Concepcion N.F., Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8(2):266-272.
31. Poolman J.T., Frasch C.E., Kayhty H., Lestrate P., Madhi S.A., Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010, 17(1):134-142.
32. WHO. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. [14.04.11]. http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_2010.pdf.
33. Örtqvist A., Henckaerts I., Hedlund J., Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007, 25(13):2445-2450.
34. Almeida V.D.C., Mussi-Pinhata M.M., Souza C.B.S.D., Kubo C.A., Martinez E.Z., Carneiro-Sampaio M.M., et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants. Vaccine 2009, 27(29):3856-3861.
35. Pomat W.S., Lehmann D., Sanders R.C., Lewis D.J., Wilson J., Rogers S., et al. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 1994, 62(5):1848-1853.
36. Lloyd-Evans N.M., O'Dempsey T.J.D.M., Baldeh I.M., Secka O.B., Demba E.M., Todd J.E.M., et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 1996, 15(10):866-871.
37. Moore Matthew R., Gertz Robert E.J., Woodbury Robyn L., Barkocy-Gallagher Genevieve A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197(7):1016-1027.
38. Klemets P., Lyytikäinen O., Ruutu P., Kaijalainen T., Leinonen M., Ollgren J., et al. Trends and geographical variation in invasive pneumococcal infections in Finland. Scand J Infect Dis 2008, 40(8):621-628.
39. Groneck L., Schrama D., Fabri M., Stephen T.L., Harms F., Meemboor S., et al. Oligoclonal CD4+ T cells promote host memory immune responses to zwitterionic polysaccharide of Streptococcus pneumoniae. Infect Immun 2009, 77(9):3705-3712.
40. Kalka-Moll W.M., Tzianabos A.O., Bryant P.W., Niemeyer M., Ploegh H.L., Kasper D.L. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol 2002, 169(11):6149-6153.
41. Klein D., Steinhoff M., Zaman K., Martinez J., Hickey M. Maternal pneumococcal antibody and active immune response to pneumococcal vaccine in infants. Proceedings of the 7th international symposium on pneumococci and pneumococcal infections 2010 2010, [Abstr 31].
42. Nohynek H., Gustafsson L., Capeding M.R., Kayhty H., Olander R.M., Pascualk L., et al. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr Infect Dis J 1999, 18(1):25-30.
43. Siegrist C.-A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412.
44. Borgoño J., McLean A., Vella P., Woodhour A., Canepa I., Davidson W., et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978, 157(1):148-154.
45. Lawrence E., Edwards K., Schiffman G., Thompson J., Vaughn W., Wright P. Pneumococcal vaccine in normal children. Primary and secondary vaccination. Am J Dis Child 1983, 137(9):846-850.
46. MacLennan J., Obaro S.K., Deeks J., Williams D., Pais L.B., Carlone G., et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999, 17(23-24):3086-3093.
47. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.-A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201(10):1570-1579.
48. Väkeväinen M., Soininen A., Lucero M., Nohynek H., Auranen K., Mäkelä P.H., et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010, 157(5):778-783.
49. Lazarus R., Clutterbuck E., Angus B., Peto T., Peter B., Mant D., et al. Immune response to 23-valent pneumococcal polysaccharide vaccine following a 1 or 2 dose priming with heptavalent pneumococcal conjugate vaccine. Proceedings of the 7th international symposium on pneumococci and pneumococcal infections 2010, [Abstr 146].
50. O'Grady K-Ann F., Lee Katherine J., Carlin John B., Torzillo Paul J., Chang Anne B., Mulholland E.K., et al. Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5-23 months of age following pneumococcal vaccination: a cohort study. Clin Infect Dis 2010, 50(7):970-978.
51. Henckaerts I., Goldblatt D., Ashton L., Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13(3):356-360.
52. Inostroza J., Villanueva S., Mason K., Leiva L.E., Sorensen R.U. Effects of absorption with pneumococcal type 22F polysaccharide on maternal, cord blood, and infant Immunoglobulin G antipneumococcal polysaccharide antibodies. Clin Diagn Lab Immunol 2005, 12(6):722-726.